Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Alzheimer's type dementia, rated as severe~* progressive worsening of memory and other cognitive functions~* brain imaging (CTor MRI scan) within last 3 years~* ability to be mobile (aided or unaided) with sufficient vision and hearing to comply with testing.~Exclusion Criteria:~* Dementia caused by cerebrovascular disease~* disturbances of consciousness, delirium, psychosis~* severe aphasia~* or major sensorimotor impairment~* cognitive impairment due to acute cerebral trauma, hypoxic cerebral damage, vitamin deficiency, infections, primary of metastatic cerebral neoplasia, endocrine or metabolic disease or mental retardation, pregnant or nursing women or those without adequate contraception.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).